IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake

ImmunityBio IBRX reported an adjusted loss of 8 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 9 cents. The loss improved 20% compared with the year-ago period’s loss of 10 cents.

Total revenues surged nearly 94% year over year to $51.2 million, beating the Zacks Consensus Estimate of $48.5 million.

Year to date, shares of ImmunityBio have skyrocketed 251% compared with the industry’s nearly 3% growth.

Image Source: Zacks Investment Research

IBRX's Product Revenue Hits a Record

The top-line performance reflected continued adoption of the company’s sole marketed drug, Anktiva, among U.S. urologists and strong market access. Net product revenues, which accounted for nearly all quarterly revenues, reached a record $50.7 million, rising 92% year over year and 15% sequentially.

The product performance marked ImmunityBio’s eighth consecutive quarter of sequential net product revenue growth since Anktiva’s commercial launch.

Other revenues totaled $0.6 million.

ImmunityBio Faces Higher Operating Costs

Total operating costs and expenses increased about 16% year over year to around $113 million.

Research and development expenses grew 10% to nearly $61 million. The increase reflected higher personnel-related costs, clinical trial expenses and external manufacturing and distribution costs.

Selling, general and administrative expenses climbed 22% year over year to about $52 million. The increase stemmed mainly from higher professional services, personnel-related and commercial expenses.

IBRX Advances Anktiva’s Regulatory Reach

Last month, the United Arab Emirates granted broad marketing authorization for Anktiva across BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for carcinoma in situ (CIS) and papillary disease, as well as metastatic non-small cell lung cancer (NSCLC). The authorization expanded Anktiva’s regulatory footprint.

An FDA filing is under review, seeking label expansion for Anktiva plus BCG in patients with BCG-unresponsive NMIBC with papillary disease without CIS. A final decision is expected by Jan. 6, 2027.

ImmunityBio also intends to submit another regulatory filing later this year, seeking to expand Anktiva’s label in patients with BCG-naïve NMIBC with CIS, with or without papillary disease. Multiple regulatory, clinical and data milestones are expected over the next 12 months.

IBRX’s Zacks Rank

Iovance currently carries a Zacks Rank #3 (Hold).

ImmunityBio, Inc. Price

 

ImmunityBio, Inc. price | ImmunityBio, Inc. Quote

Our Key Picks Among Biotech Stocks

Some better-ranked stocks in the biotech sector are Harmony Biosciences HRMY and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, earnings per share (EPS) estimates for Harmony Biosciences have risen from $3.20 to $3.33 for 2026. Over the same period, EPS estimates have increased from $3.64 to $3.87 for 2027. HRMY shares have about 4% year to date.

Harmony Biosciences missed earnings in three of the trailing four quarters while meeting on one occasion, delivering an average negative surprise of 13.97%.

Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $3.02 from $2.97. Over the same period, EPS estimates for 2027 have risen from $4.81 to $5.31. LQDA shares have skyrocketed 156% so far this year.

Liquidia’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 54.40%.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research